O4 Hubs detail
O4 1 Column (Full)
O4 Text Component

Report

New first-in-class therapies for 2022

View the Q1 2022 OptumRx Drug Pipeline Insights Report.

O4 2 Columns (1/4 - 3/4)
O4 Text Component

Every new year brings new drug approvals. Following the theme of our previous OptumRx Drug Insights Report, we analyze three new drugs with an expected FDA decision by the end of the first quarter of 2022.

In this latest quarterly Drug Pipeline Insights Report, OptumRx reviews several potential first-in-class therapies, including those for:

  • Severe asthma
  • Long-acting prevention of HIV in at-risk individuals
  • Anemia associated with chronic kidney disease

O4 Text Component
O4 Text Component

Don't want to read the full report? Download the brief summary.

O4 Text Component

Related Content

O4 Complex Card

Hemophilia: Extremely rare, extremely expensive

Better management strategies and new treatments emerge
Learn more
O4 Complex Card

The dangers of polypharmacy

Millions of workers at risk due to overprescribed drugs
Learn more
O4 Complex Card

Drug pricing spotlight: Wound care

Combat against brand name products costing 125 times more.
Learn more

Learn how we can help solve your challenges

Request more information